| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3002991 | Nutrition, Metabolism and Cardiovascular Diseases | 2006 | 7 Pages |
AimsThe endocannabinoid system modulates synaptic neurotransmission centrally and peripherally and is involved in the brain pathways concerned with addiction, central regulation of body weight and adipose tissue function. The system is overactivated in animal models of obesity and nicotine use. This review discusses the role of rimonabant, a cannabinoid receptor 1 blocker, which has undergone Phase III clinical testing, in the treatment of obesity and tobacco dependence.Data synthesisResults of Phase III clinical trials have shown that rimonabant has promising efficacy in the treatment of obesity, dyslipidaemia and diabetes associated with obesity, in preventing weight gain following smoking cessation, and possibly in smoking cessation. No critical problems with the tolerance and safety of the compound have appeared in studies to date.ConclusionRimonabant may prove to be a useful aid in the treatment of the most widespread cardiometabolic risk factors.
